Y Intercept Hong Kong Ltd Acquires 98,520 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Y Intercept Hong Kong Ltd increased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 777.2% during the third quarter, HoldingsChannel reports. The fund owned 111,196 shares of the company’s stock after acquiring an additional 98,520 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Teva Pharmaceutical Industries were worth $2,246,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of TEVA. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $41,000. Cromwell Holdings LLC increased its holdings in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the period. Sound Income Strategies LLC raised its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares during the last quarter. MAI Capital Management lifted its stake in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares during the period. Finally, JTC Employer Solutions Trustee Ltd acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $65,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares in the company, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 in the last three months. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 2.1%

Shares of TEVA stock opened at $33.21 on Thursday. The company has a market capitalization of $38.09 billion, a P/E ratio of 55.35, a P/E/G ratio of 1.85 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $33.42. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a 50-day moving average price of $30.12 and a 200 day moving average price of $22.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 4.24% and a return on equity of 46.13%. The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 beat — Teva reported EPS of $0.96 vs. $0.65 consensus and revenue of $4.71B vs. $4.36B consensus; revenue was up ~11% YoY, and management highlighted margin improvement and solid branded drug sales. Earnings Release / Slide Deck
• Positive Sentiment: Pipeline & milestone upside — Teva booked a milestone payment tied to starting a late‑stage study in ulcerative colitis/Crohn’s and emphasized pipeline progress, which supports growth expectations beyond generics. Teva profit, revenue rise (Reuters)
• Neutral Sentiment: 2025 full‑year results show continued growth — Teva reported 2025 revenue of $17.3B (≈+3% YoY) and called out execution on its pivot‑to‑growth strategy; positive for medium‑term thesis but not an immediate catalyst. GlobeNewswire: FY2025 results
• Neutral Sentiment: Brand / awareness push — Teva announced a patient‑awareness campaign for Huntington’s disease with Will Forte; good for reputation and long‑term franchise building but limited near‑term financial impact. GlobeNewswire: Honestly HD
• Negative Sentiment: Guidance tempered — Management set FY2026 EPS guidance of $2.57–$2.77 (vs. ~$2.71 consensus midpoint) and revenue guidance of $16.4B–$16.8B below the ~$17.0B consensus; that revenue range is the main reason upside from the quarter could be capped. Guidance in earnings release
• Neutral Sentiment: Analyst view: value appeal — Some analysts (Zacks) flag TEVA as a strong value stock based on style scores, which could attract long‑term buyers but is not an immediate catalyst. Zacks: Value stock note

Analyst Ratings Changes

Several research firms have commented on TEVA. Barclays started coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target for the company. Bank of America upped their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.